Complete metabolic response following anaplastic lymphoma kinase (ALK) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence in situ hybridisation discordant ALK test results.

Chazan, Grace; Forbes, Danielle; Murugasu, Anand; Wong, Hui-Li; Solomon, Benjamin

Chazan, Grace; Forbes, Danielle; Murugasu, Anand; Wong, Hui-Li; Solomon, Benjamin.

Afiliação

Chazan G; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Forbes D; Department of Medical Oncology, Western Health, Melbourne, Victoria, Australia.
Murugasu A; Department of Pathology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Wong HL; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Solomon B; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.

Intern Med J ; 51(8): 1355-1356, 2021 Aug.

Article em En | MEDLINE | ID: mdl-34423539

Assuntos

Adenocarcinoma; Neoplasias Pulmonares; Neoplasias Primárias Desconhecidas; Adenocarcinoma/tratamento farmacológico; Adenocarcinoma/genética; Quinase do Linfoma Anaplásico/genética; Humanos; Imuno-Histoquímica; Hibridização in Situ Fluorescente; Neoplasias Pulmonares/tratamento farmacológico; Neoplasias Pulmonares/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Primárias Desconhecidas / Adenocarcinoma / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google